MaxCyte Reports Q3 2025 Financial Results, Reiterates Full-Year Guidance

miércoles, 12 de noviembre de 2025, 4:06 pm ET1 min de lectura
MXCT--

MaxCyte reported Q3 2025 financial results with core business revenue of $6.4 million and total revenue of $6.8 million. The company added a new SPL client, Moonlight Bio, and reiterated its full-year 2025 revenue guidance. Total cash, cash equivalents, and investments were $158.0 million as of September 30, 2025.

MaxCyte Reports Q3 2025 Financial Results, Reiterates Full-Year Guidance

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios